#top-leaderboard-ads, .stickyads { position: static !important; }

What an Oral Option Means for Psoriasis Care

Featuring:

BLBenjamin Lockshin, MDFaculty

Updated:Oct 20, 2025

Psoriasis Psoriasis

About this video

In this video, Ben Lockshin, MD, shares his perspective on the evolving role of oral therapies in psoriasis care. He highlights how a once-daily oral option offers strong efficacy, durability, and safety, while also meeting patient demand for alternatives to injections. With practical insights on tolerability, monitoring, and long-term outcomes, Dr Lockshin explains why oral therapy is becoming an important first-line consideration for patients eligible for systemic treatment.

Continuing Education

1 Credit

DermInsider - Session 1

In the first DermInsider - A Virtual Grand Rounds Series session of the year, join leading experts Dr. Bhutani and Dr. Serota for a dynamic deep dive into one of the most exciting frontiers in psoriatic disease management. Dr. Del Rosso moderates this 45-minute activity that explores the rapidly emerging role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their potential impact beyond metabolic disease. Don't miss out on this opportunity to catch up on breakthrough insights and emerging evidence on this hot topic!“We have some really interesting data on the horizon that’s going to hopefully help more providers feel confident about using [GLP-1] medications in conjunction with their psoriasis medications that they are used to using.” – Tina Bhutani, MD MASBest of FC25: GLP-1RAs in Psoriasis – Catching Up on The ScienceThis activity is supported by an educational grant from Lilly.

0.25 Credits

5 Tips in 5 Minutes: Co-Managing Psoriasis and Obesity With GLP-1 Receptor Agonists

Got a few minutes? Join our expert faculty for their rapid-fire tips on getting started with GLP-1 receptor agonists for patients with psoriasis and obesity.“When we are treating patients with obesity and psoriasis in weight management, really focus on the health gains. It’s not about what people are losing, it’s about what they are gaining in this process.” – Angela Fitch, MDPlease visit the “Educational Resources” page to access the handouts developed by faculty on GLP's in psoriatic disease mentioned in this activity.This activity is supported by an educational grant from Lilly.

0.5 Credits

Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis

In this 20-minute Seminar in Depth from the 2025 Fall Clinical Dermatology Conference, the faculty explore what differentiates TYK2 inhibitors from traditional JAK inhibitors, as well as how to identify patients with psoriasis who may benefit from oral small molecule therapy.“When thinking about a medication, you need to take a number of things into consideration: location of disease, disease severity, and age. Age plays a big role when I think about what medication I’m going to choose for a patient – Are they of child-bearing age? Are they young and they live in group housing or a dorm?” – Benjamin Lockshin, MDFC25: Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis: An Online ActivityThis activity is supported by an educational grant from Bristol Myers Squibb.